Compare Charles River Laboratories Intl. Inc (CRL) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Fox Corp Class B — how do they compare? Charles River Laboratories Intl. Inc trades at $227.54 (market cap $11.14B), while Fox Corp Class B trades at $50.37 (market cap $21.85B). The key difference: Fox Corp Class B is the larger of the two by market cap, and Fox Corp Class B pays a 1.13% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | FOX | |
|---|---|---|
Market Cap | $11.14B | $21.85B |
Sector | Health | Media |
52-Week High | $233.60 | $67.76 |
52-Week Low | $145.57 | $44.39 |
Enterprise Value | $14.00B | $25.83B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FOX trades at $50.22, up 3.02% with bullish technical signals and strong earnings beats. Recent Q1 2026 EPS of $1.32 exceeded expectations by 33.6%, continuing a pattern of outperformance. The company shows improved cash flow with 2025 operating cash flow reaching $3.32 billion, while revenue grew to $16.30 billion. Technical indicators show mixed signals with RSI at neutral levels but ADX suggesting strong trend momentum.
The outlook remains positive with analyst price targets suggesting 27-39% upside potential. Key risks include competitive pressures in streaming and potential volatility from the recent Roku acquisition. Wall Street sentiment is cautiously optimistic with 43% buy ratings, though the stock faces near-term execution challenges with projected 2026 cash flow turning negative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
